Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
-
REGULATORY Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
-
REGULATORY MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
-
ORGANIZATION Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
-
BUSINESS Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
-
BUSINESS AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
-
REGULATORY Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
-
REGULATORY Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
-
BUSINESS Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
-
BUSINESS Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
-
REGULATORY Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
-
BUSINESS Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
-
REGULATORY Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
-
REGULATORY Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
-
BUSINESS Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
-
BUSINESS MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
-
REGULATORY Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
-
BUSINESS Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
-
REGULATORY MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
-
BUSINESS Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…